O Shaughnessy Asset Management LLC Sells 28,190 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

O Shaughnessy Asset Management LLC trimmed its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 13.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,599 shares of the company’s stock after selling 28,190 shares during the quarter. O Shaughnessy Asset Management LLC owned 0.06% of Amneal Pharmaceuticals worth $1,391,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in AMRX. Prudential Financial Inc. grew its stake in Amneal Pharmaceuticals by 29.6% in the fourth quarter. Prudential Financial Inc. now owns 1,183,781 shares of the company’s stock valued at $9,376,000 after acquiring an additional 270,200 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company’s stock valued at $117,548,000 after purchasing an additional 218,025 shares in the last quarter. Fox Run Management L.L.C. grew its position in shares of Amneal Pharmaceuticals by 69.0% in the 4th quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company’s stock valued at $162,000 after purchasing an additional 8,342 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Amneal Pharmaceuticals during the 4th quarter worth approximately $219,000. Finally, Sei Investments Co. raised its holdings in Amneal Pharmaceuticals by 14.4% during the 4th quarter. Sei Investments Co. now owns 339,461 shares of the company’s stock worth $2,689,000 after buying an additional 42,743 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $7.38 on Friday. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -10.85 and a beta of 1.06. The firm has a 50-day moving average of $8.36 and a 200-day moving average of $8.35. Amneal Pharmaceuticals, Inc. has a one year low of $5.18 and a one year high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The company had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. During the same period last year, the company posted $0.14 earnings per share. As a group, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AMRX. Barclays increased their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Finally, StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $10.80.

Insider Buying and Selling

In other news, Director Gautam Patel sold 62,590 shares of the business’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total transaction of $501,345.90. Following the transaction, the director now directly owns 1,968,886 shares in the company, valued at $15,770,776.86. The trade was a 3.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares of the company’s stock, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,222,590 shares of company stock worth $43,614,546. Insiders own 17.46% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.